Current Hematologic Malignancy Reports

, Volume 3, Issue 3, pp 119–125 | Cite as

Late complications after treatment for Hodgkin lymphoma

Article

Abstract

Long-term survivors of Hodgkin lymphoma face a number of late effects that can significantly affect the length and quality of their life. These include increased risk of second malignancy, cardiovascular disease, pulmonary dysfunction, infections, and endocrinopathy. Of these late effects, second malignancies and cardiac disease are the two leading contributors to the excess mortality seen in long-term Hodgkin lymphoma survivors. An improved understanding of the range of late complications after Hodgkin lymphoma therapy and the identification of treatment-related and patient-related risk factors can guide the development of screening and prevention programs for long-term survivors who have completed treatment. In addition, increasing recognition of late complications has in part led to substantial changes in the treatment of Hodgkin lymphoma over the years. Continued long-term follow-up of patients treated with modern therapy and documentation of late effects associated with newer treatment will be essential.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hoppe RT: Hodgkin’s disease: complications of therapy and excess mortality. Ann Oncol 1997, 8:115–118.PubMedCrossRefGoogle Scholar
  2. 2.
    Ng AK, Bernardo MP, Weller E, et al.: Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 2002, 20:2101–2108.PubMedCrossRefGoogle Scholar
  3. 3.
    Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al.: Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003, 21:3431–3439.PubMedCrossRefGoogle Scholar
  4. 4.
    van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al.: Leukemia risk following Hodgkin’s disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994, 12:1063–1073.PubMedGoogle Scholar
  5. 5.
    Kaldor JM, Day NE, Clarke EA, et al.: Leukemia following Hodgkin’s disease. N Engl J Med 1990, 322:7–13.PubMedGoogle Scholar
  6. 6.
    Schonfeld SJ, Gilbert ES, Dores GM, et al.: Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst 2006, 98:215–218.PubMedGoogle Scholar
  7. 7.
    Ng AK, Bernardo MV, Weller E, et al.: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002, 100:1989–1996.PubMedCrossRefGoogle Scholar
  8. 8.
    Diehl V, Franklin J, Pfreundschuh M, et al.: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003, 348:2386–2395.PubMedCrossRefGoogle Scholar
  9. 9.
    Rueffer U, Josting A, Franklin J, et al.: Non-Hodgkin’s lymphoma after primary Hodgkin’s disease in the German Hodgkin’s Lymphoma Study Group: incidence, treatment, and prognosis. J Clin Oncol 2001, 19:2026–2032.PubMedGoogle Scholar
  10. 10.
    Swerdlow AJ, Barber JA, Hudson GV, et al.: Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000, 18:498–509.PubMedGoogle Scholar
  11. 11.
    van Leeuwen FE, Klokman WJ, Veer MB, et al.: Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000, 18:487–497.PubMedGoogle Scholar
  12. 12.
    Travis LB, Hill DA, Dores GM, et al.: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290:465–475.PubMedCrossRefGoogle Scholar
  13. 13.
    van Leeuwen FE, Klokman WJ, Stovall M, et al.: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 2003, 95:971–980.PubMedCrossRefGoogle Scholar
  14. 14.
    Travis LB, Gospodarowicz M, Curtis RE, et al.: Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002, 94:182–192.PubMedGoogle Scholar
  15. 15.
    Girinsky T, van der Maazen R, Specht L, et al.: Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79:270–277.PubMedCrossRefGoogle Scholar
  16. 16.
    Hodgson DC, Koh ES, Tran TH, et al.: Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007, 110:2576–2586.PubMedCrossRefGoogle Scholar
  17. 17.
    Swerdlow AJ, Schoemaker MJ, Allerton R, et al.: Lung cancer after Hodgkin’s disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001, 19:1610–1618.PubMedGoogle Scholar
  18. 18.
    Heidenreich PA, Hancock SL, Lee BK, et al.: Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003, 42:743–749.PubMedCrossRefGoogle Scholar
  19. 19.
    Hull MC, Morris CG, Pepine CJ, et al.: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003, 290:2831–2837.PubMedCrossRefGoogle Scholar
  20. 20.
    Adams MJ, Lipsitz SR, Colan SD, et al.: Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 2004, 22:3139–3148.PubMedCrossRefGoogle Scholar
  21. 21.
    Glanzmann C, Huguenin P, Lutolf UM, et al.: Cardiac lesions after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 1994, 30:43–54.PubMedCrossRefGoogle Scholar
  22. 22.
    Heidenreich PA, Hancock SL, Vagelos RH, et al.: Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005, 150:977–982.PubMedCrossRefGoogle Scholar
  23. 23.
    Aviles A, Neri N, Nambo JM, et al.: Late cardiac toxicity secondary to treatment in Hodgkin’s disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 2005, 46:1023–1028.PubMedCrossRefGoogle Scholar
  24. 24.
    Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al.: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007, 109:1878–1886.PubMedCrossRefGoogle Scholar
  25. 25.
    Boivin JF, Hutchison GB, Lubin JH, et al.: Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer 1992, 69:1241–1247.PubMedGoogle Scholar
  26. 26.
    Cosset JM, Henry-Amar M, Pellae-Cosset B, et al.: Pericarditis and myocardial infarctions after Hodgkin’s disease therapy. Int J Radiat Oncol Biol Phys 1991, 21:447–449.PubMedGoogle Scholar
  27. 27.
    Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993, 270:1949–1955.PubMedCrossRefGoogle Scholar
  28. 28.
    Swerdlow AJ, Higgins CD, Smith P, et al.: Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007, 99:206–214.PubMedCrossRefGoogle Scholar
  29. 29.
    Heidenreich PA, Schnittger I, Strauss HW, et al.: Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol 2007, 25:43–49.PubMedCrossRefGoogle Scholar
  30. 30.
    Bowers DC, McNeil DE, Liu Y, et al.: Stroke as a late treatment effect of Hodgkin’s disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005, 23:6508–6515.PubMedCrossRefGoogle Scholar
  31. 31.
    Hirsch A, Vander Els N, Straus DJ, et al.: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in earlystage Hodgkin’s disease. J Clin Oncol 1996, 14:1297–1305.PubMedGoogle Scholar
  32. 32.
    Martin WG, Ristow KM, Habermann TM, et al.: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005, 23:7614–7620.PubMedCrossRefGoogle Scholar
  33. 33.
    Oldervoll LM, Kaasa S, Knobel H, et al.: Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors—results from a pilot study. Eur J Cancer 2003, 39:57–63.PubMedCrossRefGoogle Scholar
  34. 34.
    Mauch P, Ng A, Aleman B, et al.: Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin’s disease: July 9–16, 2003, Bellagio, Italy. Eur J Haematol 2005, 75:68–76.CrossRefGoogle Scholar
  35. 35.
    De Bruin ML, Huisbrink J, Hauptmann M, et al.: Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008, 111:101–108.PubMedCrossRefGoogle Scholar
  36. 36.
    Hodgson DC, Pintilie M, Gitterman L, et al.: Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007, 25:11–15.PubMedCrossRefGoogle Scholar
  37. 37.
    Horning SJ, Hoppe RT, Breslin S, et al.: Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630–637.PubMedCrossRefGoogle Scholar
  38. 38.
    Sieniawski M, Reineke T, Nogova L, et al.: Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008, 111:71–76.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Brigham and Women’s HospitalBostonUSA

Personalised recommendations